Michael Goldblatt

Dr. Goldblatt is an active investor in technology startups and consultant to a variety of government agencies, national laboratories and corporations. He brings over 35 years of experience in the areas of biotechnology, product development, and regulatory affairs to C₂N. Michael was Chief Executive Officer of Functional Genetics, a biotechnology company focused on target discovery and antibody therapeutics, until 2013 when its assets were acquired by its collaboration partner Elanco. Michael joined Functional Genetics in 2003, after his appointment as Director of Defense Sciences at the Defense Advanced Research Projects Agency (DARPA), and before that Dr. Goldblatt was the Science and Technology Officer for the McDonald's Corporation with broad responsibilities, including nutrition, product development, food safety and corporate venture capital. Earlier, while at General Foods, he led research efforts in the use of nutrients for pharmaceutical effects and oversaw a variety of regulatory and legal issues. Michael holds dozens of active and pending US patents, and received his J.D. and Ph.D. from the University of California at Davis and a B.A. from Reed College.